Josephine Ferreon is an assistant professor in the Department of Pharmacology, Baylor College of Medicine in Houston, Texas. Her structural biology group characterizes various intrinsically disordered proteins (IDPs), important in stem cell biology and neurodegenerative diseases, using standard and state-of-the-art biochemical/biophysical techniques such as NMR and single molecule fluorescence spectroscopy.

Many factors in materials impact foods and beverages. These range from safety issues, such as microbiological contamination, to texture issues, such as the smoothness of peanut butter.

Serge Cremers, Pharm. D., PhD, is an associate professor at Columbia University Medical Center and an attending clinical chemist at New York Presbyterian Hospital. He is the director of the Clinical Pharmacology and Toxicology Laboratory at Columbia University Medical Center and the director of the Biomarkers Core Laboratory of the Irving Institute for Clinical and Translational Research, which is home to Columbia University’s Clinical and Translational Science Award (CTSA) and the largest mass spectrometry facility at Columbia University, focusing on targeted metabolomics and the measurement of drugs. Dr Cremers’ areas of expertise are bio-analytical chemistry, translational and clinical pharmacology, therapeutic drug monitoring, as well as clinical chemistry of metabolic bone diseases. He conducts research in all of these areas and has published over 90 papers. 

Michael Rummel has held the position of chief operating officer at InSource Diagnostics, an independent laboratory that focuses on medication monitoring and compliance testing, for several years. Since graduating from the University of Wisconsin-Madison in 2005, Michael has pursued a career working in the analytical and clinical sciences. He has expertise in analytical chemistry assay development specifically with liquid chromatography/mass spectrometry, assay optimization, and sample preparation optimization and development.

Within the past few years, genomics, proteomics, and metabolomics have created new disciplines within biology while inspiring the creation of techniques and methods that take life science analytics to new levels of sensitivity, specificity and understanding.

In biopharmaceutical research and manufacturing, many processes involve sophisticated separations. One of the most advanced separation technologies is ultra-high-performance liquid chromatography (UHPLC). “There are two reasons to use UHPLC,” says Ken Cook, sales support expert, bioseparations and bio market Europe for Thermo Fisher Scientific (Waltham, MA). “The first is speed, and the second is resolution.”

First-of-its-kind system looks to increase speed and efficiency while reducing human error in analysis workflows

Sports is big business, which is why leagues and federations are desperate to keep their franchises honest. In the US, Major League Baseball (MLB) received a record $9 billion in revenues in 2014, while the National Football League took in close to $10 billion. 

High-performance liquid chromatography (HPLC) is, for many scientists, an essential chromatographic technique. HPLC systems used for the separation, identification, purification, and quantification of various chemical and biochemical solutions are composed of a pump, a sample injector, a separation column, a detection unit, and a data-processor.

Clinicians and patients alike know that traditional cancer treatments beat up the person as much as the cancer. Success arises only if the treatment kills the cancer before the patient. For decades, researchers sought solutions that attacked only the cancer, not healthy tissue.